AR091545A1 - Anticuerpos anti-egfr y usos de los mismos - Google Patents

Anticuerpos anti-egfr y usos de los mismos

Info

Publication number
AR091545A1
AR091545A1 ARP130102231A AR091545A1 AR 091545 A1 AR091545 A1 AR 091545A1 AR P130102231 A ARP130102231 A AR P130102231A AR 091545 A1 AR091545 A1 AR 091545A1
Authority
AR
Argentina
Prior art keywords
egfr
antibodies
same
egfr antibodies
binding
Prior art date
Application number
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR091545A1 publication Critical patent/AR091545A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente proporciona anticuerpos que se unen a EGFR y métodos de uso de los mismos. En ciertas realizaciones, los anticuerpos son capaces de inhibir el crecimiento de células tumorales que expresan niveles elevados de EGFR y/o inducir citotoxicidad mediada por células dependiente de anticuerpos (ADCC) de tales células. Los anticuerpos son útiles para el tratamiento de diferentes cánceres así como de otros trastornos relacionados con EGFR. Reivindicación 1: Un anticuerpo aislado o fragmento de unión al antígeno del mismo que se unen específicamente al receptor del factor de crecimiento epidérmico humano dimérico (hEGFR) con una constante de equilibrio de disociación de la unión (KD) de menos de aproximadamente 20 pM medida en un análisis de resonancia de plasmón superficial a 37ºC.
ARP130102231 2012-06-25 2013-06-25 Anticuerpos anti-egfr y usos de los mismos AR091545A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261663984P 2012-06-25 2012-06-25
US201361821000P 2013-05-08 2013-05-08

Publications (1)

Publication Number Publication Date
AR091545A1 true AR091545A1 (es) 2015-02-11

Family

ID=48782632

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102231 AR091545A1 (es) 2012-06-25 2013-06-25 Anticuerpos anti-egfr y usos de los mismos

Country Status (24)

Country Link
US (3) US9132192B2 (es)
EP (1) EP2864357B1 (es)
JP (1) JP6486268B2 (es)
KR (1) KR20150023387A (es)
CN (1) CN104411722B (es)
AR (1) AR091545A1 (es)
AU (2) AU2013280610B2 (es)
BR (1) BR112014029099A2 (es)
CA (1) CA2876697C (es)
CL (1) CL2014003465A1 (es)
CO (1) CO7160093A2 (es)
EA (1) EA030421B1 (es)
ES (1) ES2816645T3 (es)
HK (1) HK1206040A1 (es)
IL (1) IL235392B (es)
MX (1) MX356329B (es)
MY (2) MY164604A (es)
NZ (1) NZ701633A (es)
PH (1) PH12014502437A1 (es)
SG (3) SG10201804151QA (es)
TW (2) TWI641619B (es)
UY (1) UY34876A (es)
WO (1) WO2014004427A2 (es)
ZA (1) ZA201407927B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791393A3 (ru) 2011-09-30 2018-03-30 Ридженерон Фармасьютикалз, Инк. Антитела к erbb3 и их применение
US9273143B2 (en) * 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US9840560B2 (en) * 2013-03-15 2017-12-12 Alper Biotech Llc Monoclonal antibodies to EGFR, and uses therefor
ES2816624T3 (es) 2014-02-28 2021-04-05 Merus Nv Anticuerpos que se unen a EGFR y ERBB3
US20170121399A1 (en) * 2014-05-16 2017-05-04 Ablynx N.V. Improved immunoglobulin variable domains
EP3248986B1 (en) 2014-05-16 2022-01-26 Ablynx NV Immunoglobulin variable domains
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN105017424B (zh) * 2015-08-31 2021-02-09 北京泱深生物信息技术有限公司 一种egfr抗体可变区及其应用
ES2865482T3 (es) 2015-10-23 2021-10-15 Merus Nv Moléculas de unión que inhiben el crecimiento del cáncer
US20180362654A1 (en) 2015-12-11 2018-12-20 Regeneron Pharmaceuticals, Inc. Methods for Reducing or Preventing Growth of Tumors Resistant to EGFR and/or ErbB3 Blockade
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
WO2019010191A1 (en) 2017-07-06 2019-01-10 Regeneron Pharmaceuticals, Inc. CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN
CN111094351A (zh) 2017-08-09 2020-05-01 美勒斯公司 结合EGFR和cMET的抗体
WO2019114793A1 (zh) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
JP7321159B2 (ja) 2017-12-22 2023-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 薬剤生成物不純物を特性決定するためのシステム及び方法
MX2020008095A (es) 2018-01-31 2020-09-24 Regeneron Pharma Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
JP2021514609A (ja) 2018-02-28 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ウイルス混入物質を同定するためのシステムおよび方法
KR20200131838A (ko) * 2018-03-14 2020-11-24 에프. 호프만-라 로슈 아게 항체의 친화성 성숙화를 위한 방법
TW202323813A (zh) 2018-03-19 2023-06-16 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CN108680746A (zh) * 2018-06-05 2018-10-19 中国科学院合肥物质科学研究院 一种控制肺癌细胞活力的分子靶标及其应用
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
EP3775926A1 (en) 2018-08-30 2021-02-17 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN117110492A (zh) 2019-01-16 2023-11-24 瑞泽恩制药公司 鉴别蛋白质中的游离巯基的方法
EP3941941A1 (en) 2019-03-22 2022-01-26 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
CA3135004A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
EP4005593A4 (en) * 2019-07-24 2023-08-16 Sinocelltech Ltd. MULTI-VARIABLE DOSE DELIVERY METHOD FOR USE IN THE TREATMENT OF CANCER IN WHICH EGFR IS STRONGLY EXPRESSED
US20220323937A1 (en) 2019-09-24 2022-10-13 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
KR20220104797A (ko) 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
IL294765B2 (en) 2020-01-21 2023-12-01 Regeneron Pharma Deglycosylation methods for electrophoresis of glycosylated proteins
AU2021227687B2 (en) 2020-02-26 2023-02-23 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2 and methods of using the same
US20220064591A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
TW202237070A (zh) 2020-11-25 2022-10-01 美商再生元醫藥公司 使用非水性膜乳化之持續釋放調配物
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CA3202197A1 (en) 2021-01-20 2022-07-28 Reginald Smith Methods of improving protein titer in cell culture
CA3207883A1 (en) 2021-03-03 2022-09-09 Xiaobin Xu Systems and methods for quantifying and modifying protein viscosity
CA3211302A1 (en) 2021-03-26 2022-09-29 Ross Kenyon Methods and systems for developing mixing protocols
WO2022240757A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
AU2022286340A1 (en) 2021-06-01 2024-01-04 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
WO2023044139A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
TW202323817A (zh) 2021-10-07 2023-06-16 美商再生元醫藥公司 Ｐｈ建模及控制之系統及方法
US20230110811A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. pH METER CALIBRATION AND CORRECTION
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
CN116333119B (zh) * 2021-12-16 2024-02-23 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
US20230296559A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
US20240027432A1 (en) 2022-07-13 2024-01-25 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes
WO2024076926A1 (en) 2022-10-03 2024-04-11 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
CN117430707B (zh) * 2023-10-25 2024-04-19 重庆天科雅生物科技有限公司 一种cik细胞的制备方法及其在治疗癌症中的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ES2191702T3 (es) 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
JP4398644B2 (ja) * 2001-04-06 2010-01-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア ＥｒｂＢ界面ペプチド擬態およびその使用方法
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1417232B1 (en) 2001-06-13 2014-12-03 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
WO2003012072A2 (en) * 2001-08-03 2003-02-13 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
EP2263691B1 (en) * 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
WO2005079434A2 (en) * 2004-02-17 2005-09-01 The University Of North Carolina At Chapel Hill Modulation of epidermal growth factor heterodimer activity
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CN101321784A (zh) * 2005-10-11 2008-12-10 埃博灵克斯股份有限公司 针对egfr和igf－ir的纳米抗体tm和多肽
US7723484B2 (en) 2005-11-12 2010-05-25 Applied Molecular Evolution, Inc. Anti-EGFR antibodies
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
PT2374818E (pt) 2006-06-02 2013-02-13 Regeneron Pharma Anticorpos com elevada afinidade para o receptor il-6 humano
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
TWI574698B (zh) * 2008-03-18 2017-03-21 建南德克公司 抗ｈｅｒ２抗體-藥物結合物及化療劑之組合及使用方法
TWI496582B (zh) * 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
RU2504553C2 (ru) * 2009-03-20 2014-01-20 Дженентек, Инк. Антитела к her
MX2011010158A (es) * 2009-04-07 2011-10-17 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-2/anti-c-met.
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011156617A2 (en) * 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies

Also Published As

Publication number Publication date
CN104411722A (zh) 2015-03-11
AU2013280610B2 (en) 2018-04-26
AU2013280610A1 (en) 2014-11-20
MX356329B (es) 2018-05-24
UY34876A (es) 2013-12-31
ZA201407927B (en) 2015-11-25
SG11201407163XA (en) 2014-11-27
EA201590085A1 (ru) 2015-04-30
TWI641619B (zh) 2018-11-21
KR20150023387A (ko) 2015-03-05
US20130344093A1 (en) 2013-12-26
AU2018204895A1 (en) 2018-07-26
TW201843172A (zh) 2018-12-16
PH12014502437B1 (en) 2015-01-12
WO2014004427A8 (en) 2014-12-18
EP2864357A2 (en) 2015-04-29
MX2014014361A (es) 2015-02-05
EA030421B1 (ru) 2018-08-31
JP6486268B2 (ja) 2019-03-20
CA2876697C (en) 2021-07-13
US20180036405A1 (en) 2018-02-08
EP2864357B1 (en) 2020-07-01
CO7160093A2 (es) 2015-01-15
US20150337043A1 (en) 2015-11-26
MY164604A (en) 2018-01-30
US9132192B2 (en) 2015-09-15
SG10201610590UA (en) 2017-02-27
US9789184B2 (en) 2017-10-17
HK1206040A1 (en) 2015-12-31
CA2876697A1 (en) 2014-01-03
BR112014029099A2 (pt) 2017-07-18
NZ701633A (en) 2017-08-25
CN104411722B (zh) 2017-11-17
MY181086A (en) 2020-12-17
ES2816645T3 (es) 2021-04-05
WO2014004427A2 (en) 2014-01-03
SG10201804151QA (en) 2018-07-30
CL2014003465A1 (es) 2015-02-27
PH12014502437A1 (en) 2015-01-12
JP2015521629A (ja) 2015-07-30
IL235392B (en) 2019-02-28
TW201402610A (zh) 2014-01-16
WO2014004427A3 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
AR091545A1 (es) Anticuerpos anti-egfr y usos de los mismos
CL2017001729A1 (es) Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20; y usos de los mismos.
MX2021013336A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
DOP2018000212A (es) Moléculas de unión a bcma y métodos de uso de las mismas
CR20190095A (es) Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos
MX2020004410A (es) Anticuerpos biespecificos con funciones efectoras reducidas.
CO2020008972A2 (es) Nanopartícula de lípido que contiene ácido nucleico y uso de la misma
EA201891641A1 (ru) Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
AR089010A1 (es) Anticuerpos anti-pd-l1 y sus usos
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
CO6280500A2 (es) Anticuerpos humanizados especificos pare l factor von willebrand
CY1115349T1 (el) Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου
WO2011156617A3 (en) Anti-egfr antibodies
EA201370196A1 (ru) Антитела, которые связывают фактор роста опухоли-альфа и эпирегулин
AR105553A1 (es) Anticuerpo del receptor del factor 1 del crecimiento similar a insulina (igf-1r) y su utilización para diagnosticar cáncer
AR099798A1 (es) Métodos y composiciones de anticuerpos para el tratamiento de tumores
AR109345A1 (es) Receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
AR101721A1 (es) Anticuerpos y receptores de antígenos quiméricos específicos para cd19
CU20130079A7 (es) Uso de células t modificadas por receptor de antígeno quimérico para tratar cáncer